Registration - Consultant Lobbyist
Moderna Biopharma Canada Corporation / Matthew Mitschke, Consultant Lobbyist
Registration Information
Lobbyist name: Matthew Mitschke, Consultant Lobbyist
Initial registration start date: 2026-03-06
Registration status: Active
Projected end date: No date provided
Registration number: 8761-6477
Associated Lobbying Activity Reports
Total number of Lobbying Activity Reports: 0
Lobbying Activity Reports - last 6 months: 0
Version 2 of 2 (2026-03-06 to present)
Version 2 of 2 (2026-03-06 to present)
Lobbying Information
Details Regarding the Identified Subject Matter |
|||||||
| Will the consultant lobbyist be arranging meetings between a public office holder and the client for the purpose of attempting to influence any of the matters listed: | Yes | ||||||
|
|||||||
BC Ministries/Provincial Entities
- Finance
- Health
- Member(s) of the BC Legislative Assembly
- Office of the Premier
- Parliamentary Secretary for Seniors' Services and Long-Term Care
Contingency Information
- Payment to the consultant lobbyist by the client, in whole or in part, is not contingent on the outcome of this lobbying activity.
- Payment to the consultant lobbyist by the client, in whole or in part, is not contingent on the success in arranging a meeting with public office holders on behalf of the client.
Client Details
Client Contact Information
Moderna Biopharma Canada Corporation
Address:
155 Wellington Street W, Suite 3130
Toronto, ON M5V 3H1
Canada
Website:
modernatx.com
Description of Business Activities
Communicate with government officials in general about pharmaceutical and biotechnology policies, including those related to innovation, research and development and messenger ribonucleic acid (mRNA) technology.
Contributors to the Lobbying Activity
No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of the organization that has a direct interest in the outcome of the lobbying activity.
Government Funding in the Last 12 Months
Note: The requirement to provide all government funding requested in the last 12 months was no longer required after May 27, 2025.Received Government Funding
The Received Government Funding table below is not intended to be additive. Adding all of the entries together does not necessarily provide an accurate sum of all government funding received. There may be redundancy (reporting of the same funding more than once) caused by overlap in the "Date/Period Received" between 2 or more entries.
| Source of Government Funding | Funding Received | Date/Period Received |
|---|---|---|
| Investissement Quebec | $5,629,601.00 | 2025-12-31 |
Other Entities (working together for the purposes of lobbying) Information
Moderna Biopharma Canada Corporation is not working together with any other entity for the purpose of lobbying.
Affiliates with a Direct Interest in the Outcome
- Moderna Manufacturing Corp
-
405 Boulevard Armand-Frappier
Laval, QC H7V 4B3
Canada
-
405 Boulevard Armand-Frappier
Other Persons or Organizations with Direct Interests
The activities of Moderna Biopharma Canada Corporation are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.
Lobbyist Details
Matthew Mitschke | Former Public Office Holder Positions in BC
45 O'Connor St
Ottawa, ON K1P 1A4
Canada
Relevant Codes of Conduct
The consultant lobbyist does not have in place an undertaking to comply with any relevant codes of conduct.
Political, Sponsorship and Recall Contributions
| Consultant has lobbied, or plans to lobby a member of the Legislative Assembly, including a Minister or Premier, on behalf of this client, on or after 2024-09-21: | Yes | |||||||||||||||
|
||||||||||||||||
Gifts or Benefits Provided to Public Officer Holders
No gifts or benefits were provided to public office holdersIndividuals Hired or Subcontracted to Lobbying on behalf of the Client
No recordsConsultant Lobbyist Firm and Address
Firm: Barrack Hill Public Affairs
PO Box 632
Ottawa, ON K1P 5P7
Canada
- Date Modified: